Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

ImmunoGen Says IND For Anticancer Compound IMGN853 Is Now Active

RELATED NEWS
Trade IMGN now with 

ImmunoGen, Inc. (IMGN: Quote) announced that the Investigational New Drug, or IND, application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, non-small cell lung cancer and other epithelial malignancies which over-express folate receptor 1, or FOLR1.

The company expects Phase I evaluation of IMGN853 to commence in the middle of 2012.

Daniel Junius, president and chief executive officer, commented, "Our progress with IMGN901, IMGN529 and now IMGN853 speaks to our commitment to build and effectively advance a product pipeline of significant anticancer therapeutics. Each of these product candidates employs our TAP technology with its specific design optimized for its target. IMGN853, for example, uses one of the novel linkers we engineered to counter the multi-drug resistance that cancer cells can develop. Given the expression patterns of its target, with IMGN853 we also have a diagnostic assay to help in the identification of the patients most likely to benefit from treatment."

Click here to receive FREE breaking news email alerts for Immunogen Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
U.S. stocks edged higher on Tuesday, with the S&P 500 posting its first-ever finish above the 2,000 mark as strong economic data and a flurry of merger news contributed to buying interest. Led by energy stocks, the S&P 500 rose 2.1 points, or 0.1%, to 2,000.02 after touching an intraday record just... South Africa's leading index rose for the second straight month in June, figures from the South African Reserve Bank showed Tuesday. The composite leading index, which measures perception on future economic conditions, rose by 0.5 percent to 100.1 in June from 99.6 in the previous month. Out of ten... German business sentiment weakened for the fourth consecutive month to the lowest level in a year in August, as the escalating crisis in Ukraine and the resultant sanctions against Russia pose downside risks to the economic activity. The Ifo business climate index fell to 106.3 in August, the lowest since July 2013, from 108 a month ago, a monthly survey conducted by the Ifo institute showed.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.